Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease

2010289 citationsJournal Article

Authors

Valter Donadon · Azienda Ospedaliera Santa Maria Degli Angeli

Abstract

Our study shows that DM2 is an independent risk factor for HCC and pre-exists to HCC occurrence. In DM2 patients with HCC, metformin therapy is associated with a reduced HCC risk and seems to have a protective effect on HCC development.

Topics & Keywords

Metabolism, Diabetes, and Cancer Diabetes Treatment and Management Cancer Risks and Factors

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Liver International

Volume 30, Issue 5, pp. 750-758

DOI: 10.1111/j.1478-3231.2010.02223.x

Field-Weighted Citation Impact: 8.99